Antares Pharma Inc


ATRS

Price

3.15


Change

-0.11


High

3.27


Low

3.11


Avg Volume

669,126


PE Ratio

8.5


52 Week High

5.07


52 Week Low

3.11



Profile

Astellas Institute for Regenerative Medicine is a subsidiary of Astellas Pharma located in Marlborough, Massachusetts, US, developing stem cell therapies with a focus on diseases that cause blindness. It was formed in 1994 as a company named Advanced Cell Technology, Incorporated , which was renamed to Ocata Therapeutics in November 2014. In February 2016 Ocata acquired by Astellas for $379 million. which was finally completed in February 2016. Advanced Cell Technology was formed in 1994 and was led from 2005 to late 2010 by William M. Caldwell IV, Chairman and Chief Executive Officer. Upon Mr. Caldwell's death on December 13, 2010, Gary Rabin, a member of ACT's board of directors with experience in investment and capital raising, assumed the role of Chairman and CEO.


Top Streaming News


Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.

Data provided by IEX Cloud

About

Copyright © 2020 Finaza.IO. All Rights Reserved.